Recently, it has been observed that recombinant irisin significantly decreased the ability of breast cancer cells to proliferate and migrate, enhancing the cytotoxic activity of the common anti-neoplastic agent doxorubicin, without affecting the viability of non-malignant cells [47]. The gene discussed is FNDC5; the disease is breast carcinoma.